THE NEW GENERATION OF WEIGHT-LOSS DRUGS

Wegovy, Mounjaro, Ozempic… These new drugs drawing such intense attention have raised the hopes of millions around the world suffering from diabetes or obesity. But what are they, how are they used and who makes them?

Imitating a key hormone
These drugs imitate a hormone known as GLP-1 (it stands for glugacon-like peptide-1), which is secreted by the intestines. It stimulates insulin production and creates a feeling of fullness, suppressing the appetite.

This class of drugs is used to manage Type 2 diabetes — the most common type — and to help with weight loss.

They are administered by weekly injection, but big drug makers like Novo Nordisk, Eli Lilly and Pfizer are working to develop a pill form to be taken daily.

Side effects include nausea, vomiting and gastrointestinal troubles.


Log in to primsol.lawpavilion.com and enjoy the best E-journals, textbooks, and many more

To subscribe to Primsol, go to store.lawpavilion.com.

For further enquiries/assistance, send an email to customercare@lawpavilion.com or call 08050298729


Wegovy and Ozempic
Danish pharmaceutical giant Novo Nordisk, the world leader in diabetes treatments, uses the drug semaglutide in its Wegovy treatment for obesity and in Ozempic for Type 2 diabetes.

Wegovy received US approval in 2021. It is sold in Denmark, Norway, Britain and now Switzerland. Novo Nordisk hopes to receive French certification next year.

Ozempic got US authorization in 2017. Supply shortages there recently resulted from furious demand by people hoping to lose weight, often after seeing glowing reports from celebrities or influencers on social media.

In the United States alone, Wegovy and Ozempic are expected to generate sales, respectively, of $8.1 billion and $2.1 billion by 2031, according to a GlobalData report in March.

Mounjaro and Zepbound from Eli Lilly
Eli Lilly’s drug tirzepatide has been marketed as Mounjaro for Type 2 diabetes sufferers since US health authorities greenlighted it last year. It has also been prescribed on an “off-label” basis, that is, for purposes not specifically approved — in this case, weight loss.

Tirzepatide, to be sold as Zepbound, did receive US approval for the treatment of obesity on November 8.

Zepbound is prescribed both for the obese and for overweight patients with underlying conditions like Type 2 diabetes, elevated cholesterol or high blood pressure.

Eli Lilly sets its price at $1,060 a month.


Call Bridget Edokwe Esq on 08060798767 or send your email to barristerngblog@gmail.com

For further information on the programme Call Landline: +23492913581, +23492913524, +23492913499, +23492911209, +2349291208 Phone: +2348052128456, +2348037035989, +2349099651401. You may also visit our website: www.idrinstitute.net.
Author: Prof Theodore Okonkwo, Ph.D: CALL: 08065159968; 08068771923: PRICES: N100,000 (SPECIAL EDITION), N60,000.00 (UNIVERSAL EDITION)

Digital Evidence and eDiscovery Law Practice in Nigeria -By Emeka Arinze Esq. [ORDER NOW] - For book cost & placing order, visit www.decfi.com.ng/order


Steps To Subscribe To the Court of Appeal Reports Nigeria


Get ‘Personal Property Law in Nigeria’ By Chief Mike A.A. Ozekhome, SAN (FREE)

Click below to download FREE

https://www.pulp.up.ac.za/monographs/personal-property-law-in-nigeria

ADVERTISEMENT

BESTSELLER: Commercial and Economic Law in Nigeria By Chief Mike Ozekhome, SAN [ORDER NOW] To ORDER click the link https://kluwerlawonline.com/EncyclopediaChapter/IEL+Commercial+and+Economic+Law/COMM20210001